Nateglinide

DRUG13 trials

Sponsors

Astellas Pharma Inc, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novartis Pharmaceuticals, Atheline Major-Pedersen, University of Oslo School of Pharmacy

Conditions

Diabetes MellitusDiabetes Mellitus, Type 2Diabetes Mellitus, Type IIHealthyHealthy VolunteersImpaired Fasting GlucoseInsulin ResistancePosttransplant Diabetes Mellitus

Phase 1

Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition

CompletedNCT01159158

Dr. Reddy's Laboratories LimitedHealthy

Start: 2007-02-28End: 2007-02-28Updated: 2010-07-13

Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fed Condition

CompletedNCT01160029

Dr. Reddy's Laboratories LimitedHealthy

Start: 2004-10-31End: 2004-10-31Updated: 2010-07-13

A Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared With a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet Under Fasting Conditions in Healthy Male Subjects

CompletedNCT02088918

IlDong Pharmaceutical Co LtdHealthy Volunteers

Start: 2012-10-31Updated: 2014-03-17

Phase 2

Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients

CompletedNCT00189774

Astellas Pharma IncDiabetes Mellitus, Type II, Type 2 Diabetes Mellitus

Updated: 2008-03-13

Phase 3

A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients

CompletedNCT01316107

Astellas Pharma IncType 2 Diabetes Mellitus

Start: 2011-01-15End: 2012-10-19Updated: 2025-05-30

Phase 4

Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes

CompletedNCT00212290

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Insulin Resistance, Type 2 Diabetes Mellitus

Start: 2002-11-30End: 2006-12-31Target: 140Updated: 2010-02-15

A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion

CompletedNCT00238472

Novartis PharmaceuticalsDiabetes Mellitus, Type 2

Start: 2003-05-31End: 2005-06-30Target: 24Updated: 2012-04-27

Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference?

CompletedNCT00259168

Atheline Major-PedersenImpaired Fasting Glucose, Insulin Resistance

Start: 2003-06-30End: 2006-03-31Updated: 2018-12-03

Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients

CompletedNCT00319189

University of Oslo School of PharmacyPosttransplant Diabetes Mellitus, Posttransplant Impaired Glucose Tolerance, Renal Transplant Recipients

Start: 2002-11-30End: 2003-11-30Target: 15Updated: 2006-05-10

Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone

CompletedNCT00402909

Novartis PharmaceuticalsType 2 Diabetes

Start: 2006-11-30End: 2007-08-31Updated: 2017-02-24

The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients

CompletedNCT00437918

Inje UniversityDiabetes Mellitus, Type 2 Diabetes Mellitus

Start: 2007-01-31End: 2008-03-31Updated: 2008-03-24

Study of the Durability of Glycemic Control With Nateglinide

CompletedNCT00858013

Ajou University School of MedicineType 2 Diabetes Mellitus

Start: 2009-04-24End: 2014-06-25Updated: 2017-05-16

Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion

CompletedNCT01030952

Novartis PharmaceuticalsDiabetes Mellitus, Type 2

Start: 2009-12-31End: 2011-02-28Updated: 2012-10-19

Related Papers

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01